Study Group: Pravachol Prescribers for Hypercholesterolemia
Council Members in this Study Group: 14
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Daniel Fisher
Cardiologist
NEW YORK UNIVERSITY (INC)
Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology....
- Howard Weintraub
Clinical Director
NEW YORK UNIVERSITY (INC)Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub...
Charles GlueckMedical Research Director of Cholesterol Center
Jewish HospitalCharles Glueck, MD, is the Medical Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, interaction of atherosclerosis and thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Another piece of good news for a very good drug
November 8, 2007
Analysis by: Howard Weintraub, Clinical Director,Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level of BNP. This has not been as successful in patients without myocardial ischemia, but in those with ischemia the shortness of breath and associated chest discomfort has been helped in many. Including the most recent patient with a severe ischemic cardiomyopathy who has responded very very well with a significant increase in his functional capacity. Hopefully this news along with the safety from MERLIN and the A1C data and reduction in arrhythmias in that study will awaken docs to the benefits of Ranexa.
-
November 8, 2007
Analysis by: Howard Weintraub, Clinical Director,Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
-
June 15, 2007
Analysis by: Howard Weintraub, Clinical Director,FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com
It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in the near and mid-term future. This does not bode well for Sanofi, who will not have to regroup and pray for success with son of Amiodarone.
-
June 15, 2007
Analysis by: Howard Weintraub, Clinical Director,FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com
It is clear that the advisory panel is more concerned with safety in a limited population that the broader impact of obesity and its metabolic problems and acceleration of diabetes and atherosclerosis. This demonstrates the likelihood that the FDA will likely be posturing to reflect the rosiglitazone mess (with Baychol and Vioxx undertones). This is going to create a real challenge for Sanofi and make them pray for succes with the "son of amiodarone".
-
CETP INHIBITORS- A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC
March 6, 2007
CETP INHIBITORS: A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC | mediaroom.pfizer.com
By reducing fractional catabolic rate and by producing a large, cholesterol rich HDL molecule which could not easily be cleared by hepatic HDL receptors, our research group in Cincinnati thought from the beginning that the CETP inhibitors AS A CLASS would fail, and might even be proatherogenic. Regrettably, with torcetrapib this sequence of events seemed to occur. Our concern is that this is a class effect and that CETP inhibitors are not a fruitful area for further drug development.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Owner
- Physician - Director
- Chief Executive Officer
- Medical Director
- Physician - Department Chair
- Physician - Division Head
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
March 28, 2008 | Boston
GLGi: Lipid ManagementGLG Webcasts & Teleconferences
Leading Experts in Pravachol Prescribers for Hypercholesterolemia have not participated in any GLG webcasts.